Pharmacoeconomic analysis of alogliptin use in the treatment of type 2 diabetes
Abstract
Aim of the study: Determine the validity of alogliptin choice in comparison with other DPP-4 inhibitors, available in Russia (saxagliptin, linagliptin, vildagliptin, sitagliptin) for add-on treatment in patients with inadequate glycemic control on metformin monotherapy, basing on pharmacoeconomic analysis Methodology. Retrospective modeling was performed according to standard pharmacoeconomic methods: cost-minimization analysis, cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and sensitivity analyzes. To predict the long-term impact of the compared therapies on CUA results, a Markov model with 10-year simulation horizon has been used. Results. CEA results showed that lowering HbA1C level by 1% using alogliptin was less expensive than using other agents of the group (sitagliptin, vildagliptin, saxagliptin, linagliptin). The calculated cost per QALY gained for alogliptin therapy was 27 150 rubles, which made the use of alogliptin cost-effective. Conclusions. Alogliptin is a cost-effective alternative in comparison with any other DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin) for adding to unsuccessful metformin monotherapy.
About the Authors
S. V. Nedogoda
GBOU VPO «Volgograd State Medical University», Health Ministry of Russia
Russian Federation
Department of therapy and endocrinology Faculty of Advanced Medical
Russian Federation
Department of therapy and endocrinology Faculty of Advanced Medical
I. N. Sorokina
GBOU VPO «Volgograd State Medical University», Health Ministry of Russia
Russian Federation
Department of therapy and endocrinology Faculty of Advanced Medical
Russian Federation
Department of therapy and endocrinology Faculty of Advanced Medical
A. S. Salasiuk
GBOU VPO «Volgograd State Medical University», Health Ministry of Russia
Russian Federation
Department of therapy and endocrinology Faculty of Advanced Medical
Russian Federation
Department of therapy and endocrinology Faculty of Advanced Medical
V. O. Smirnov
GBOU VPO «Volgograd State Medical University», Health Ministry of Russia
Russian Federation
Department of therapy and endocrinology Faculty of Advanced Medical
Russian Federation
Department of therapy and endocrinology Faculty of Advanced Medical
References
1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск). // Сахарный диабет. — 2015. — Т. 18. — №. 1S.
2. Балаболкин М.И. Фармакоэкономика сахарного диабета. // Фарматека. — 2003. — Т. 16. — С. 13-16.
3. Сунцов Ю.И. и др. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007—2012 годы». // Сахарный диабет. — 2013. — №. 2S.
4. Ягудина Р.И., Куликов А.Ю., Нгуен Т. Определение «порога готовности платить» в России, в Европейских странах и в странах СНГ. // Фармакоэкономика. — №1 — 2011. С.7-12.
5. Ягудина Р.И., Сороковиков И.В. Методология проведения анализа «затраты-полезность» при проведении фармакоэкономических исследований. // Фармакоэкономика. — №2 — 2012. С.9-12.
6. Ягудина Р.И., Куликов А.Ю., Новиков И.В. Современная методология анализа чувствительности в фармакоэкономических исследованиях. // Фармакоэкономика. 2010; N4: c.8-12.
7. Ashcroft F.M., Rorsman P. Diabetes mellitus and the ? cell: the last ten years. // Cell. — 2012. — Т. 148. — №. 6. — С. 1160-1171.
8. Clarke P., Gray A., Holman R. Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62). // Medical Decision Making, Vol. 22, No. 4, 340-349 (2002).
9. Clarke P. M. et al. Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes. // Medical care. — 2009. — Т. 47. — №. 1. — С. 61-68.
10. Currie C.J. et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the fi rst 20,000 subjects. // Value in health. — 2005. — Т. 8. — №. 5. — С. 581-590.
11. Dall T.M. et al. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. // Diabetes Care. — 2014. — Т. 37. — №. 12. — С. 3172-3179.
12. Esposito K. et al. A nomogram to estimate the HbA1c response to diff erent DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. // BMJ open. — 2015. — Т. 5. — №. 2. — С. e005892.
13. Hocher B., Reichetzeder C., Alter M.L. Renal and cardiac eff ects of DPP4 inhibitors—from preclinical development to clinical research. // Kidney and Blood Pressure Research. — 2012. — Т. 36. — №. 1. — С. 65-84.
14. IMS Health (2007): Medical Ambition II — Supplement: Extension to newly diagnosed patients, Basel Switzerland; In: Novo Nordisk S/A (2007) Changing Diabetes Barometer First Report, 63.
15. International Diabetes Federation. IDF Diabetes, 7 ed. Brussels, Belgium: International Diabetes Federation, 2015. http://www.diabetesatlas.org.
16. Oxford Outcomes. Societal and patient utilities for type 2 diabetes health states: A Canadian, Australian and United Kingdom perspective, Final Report, August 12, 2011.
17. Roglic G. World Diabetes Congress 2015: Th e Global Health Challenges Stream.// Diabetes research and clinical practice. — 2015. — Т. 108. — №. 2. — С. 367-368.
18. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. // BMJ 321:405—412, 2000.
19. Wu D., Li L., Liu C. Effi cacy and safety of dipeptidyl peptidase?4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta?analysis. // Diabetes, Obesity and Metabolism. — 2014. — Т. 16. — №. 1. — С. 30-37.
Review
For citations:
Nedogoda S.V., Sorokina I.N., Salasiuk A.S., Smirnov V.O. Pharmacoeconomic analysis of alogliptin use in the treatment of type 2 diabetes. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2015;(4):43-52. (In Russ.)
Views:
3542
Email this article 